Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9

Sidoti Semi-Annual Microcap Conference 2014

PRINCETON, N.J.--()--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will present a corporate overview and update at the Sidoti & Company Semiannual Micro-Cap Conference on Friday, May 9, 2014 at 10:40 a.m. Eastern time. The conference is being held at the Grand Hyatt New York Hotel in New York City.

Management will be available for one-on-one meetings at the conference. Please contact conference organizers to schedule a meeting.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL was launched to customers in March 2014 and AMNIOMATRIX will be launched in the second quarter. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug candidate is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in preclinical testing for scar prevention/reduction. The company also offers a full product line of traditional dressings.

For more information please visit www.dermasciences.com.

Contacts

Derma Sciences, Inc.
Barry Wolfenson, 609-514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
or
Media
Rooney & Associates Communications
Chenoa Taitt, 212-223-0689
ctaitt@rooneyco.com

Sharing

Contacts

Derma Sciences, Inc.
Barry Wolfenson, 609-514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
or
Media
Rooney & Associates Communications
Chenoa Taitt, 212-223-0689
ctaitt@rooneyco.com